Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria

Fu, Hai-Xia; Zheng, Jun; Cai, Jianye; Zeng, Kaining; Yao, Jia; Chen, Liang; Li, Hui; Zhang, Jiebin; Zhang, Yingcai; Zhao, Hui; Yang, Yang

doi:10.1159/000489807

Cited by 79 publications

(74 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is contrary to previous studies focusing on other types of malignancies, while a number of studies found a positive result for NLR, PLR, LMR or SII in the role of predicting the survival for cancer patients. 5,[10][11][12][13][16][17][18][19][20][21][22] In fact, these markers also have their theoretical foundations for predicting the survival of cancer patients. For example, neutrophils could produce various factors that could promote tumor cell proliferation and invasion; lymphocytes could mediate cytotoxic cell death and inhibiting tumor cell proliferation and metastasis; monocytes in the peripheral blood reflect the status of TAM in patients, while TAM derived from monocytes inhibit immune response and promote tumor growth; elevated platelet counts could stimulate tumor angiogenesis and promote tumor metastasis.…”

Section: Discussionmentioning

confidence: 99%

<p>Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma</p>

Chen

Liu

Feng

et al. 2020

CMAR

View full text Add to dashboard Cite

The prognostic significance of inflammation-based biomarkers for neuroblastoma (NB) has not been investigated before. The aim of this study was to evaluate the prognostic value of pre-treatment inflammation biomarkers in children patients with NB. Patients and Methods: Patients diagnosed with NB from 2008 to 2016 in our institution were enrolled in this study. The clinical data and survival outcomes were retrospectively reviewed. Inflammation biomarkers or scores including C-reactive protein (CRP), albumin (ALB), Glasgow Prognostic Score (GPS), modified Glasgow Prognostic Score (mGPS), high-sensitivity modified Glasgow Prognostic Score (Hs-mGPS), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and system inflammation index (SII) were tested in this study. Univariate and multivariate survival analyses were performed to assess the prognostic value of these inflammation indicators for overall survival (OS) of children with NB. Kaplan-Meier survival curves were also conducted. Results: A total of 70 children diagnosed with neuroblastoma were enrolled in this study. NLR, PLR, LMR and SII were found to be not predictive of OS for NB patients. However, CRP, ALB, GPS and CAR were significantly associated with OS of NB patients. Multivariate analysis adjusting for age, sex, histology, tumor size, tumor stage and metastasis revealed that ALB, CAR, GPS and Hs-mGPS were significantly associated with OS of NB patients. Receiver operating characteristic (ROC) curves and Akaike Information Criterion (AIC) analyses revealed that Hs-mGPS is superior to other inflammation biomarkers in predicting OS of NB patients. Subgroup survival analysis for immature NB patients revealed similar results. Conclusion: Hs-mGPS is an effective prognostic factor for OS of patients with NB and is promising to be used as a factor for risk stratification and an indicator for more aggressive therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma</p>

Chen

Liu

Feng

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…These inflammatory indicators are expressed by inflammatory scores, such as neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), and have been reported to be associated with the prognosis of patients with malignant tumors [8,10,11]. Recently, a new inflammatory index, the systemic immune-inflammation index (SII), defined as neutrophil × platelet/lymphocyte, integrates three inflammatory cells and has been shown to be promising [12]. The prognostic value of SII has been confirmed in various cancers, including NSCLC [13], small cell lung cancer [14], esophageal squamous cell carcinoma (SqCC) [15], breast cancer [16] and hepatocellular cancer [17].…”

Section: Introductionmentioning

confidence: 99%

Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer

Xue

2020

Bioscience Reports

View full text Add to dashboard Cite

Objectives: The purpose of the present study was to evaluate the prognostic value of a systemic immune-inflammation index (SII) and the relationship between SII and the effectiveness of postoperative treatment in patients with non-small cell lung cancer (NSCLC). Methods: A total of 538 patients diagnosed with NSCLC who had undergone curative surgery were retrospectively enrolled in the study. Clinicopathologic and laboratory variables were collected. SII was defined as neutrophil × platelet/lymphocyte counts. Both univariate and multivariate analyses were performed to analyze the prognostic value of these factors. Results: The preoperative SII level was associated with sex, smoking history, histological type, lesion type, resection type, pathological stage, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), fibrinogen and bone metastasis (P<0.05). The univariate and multivariate analyses revealed that SII was an independent prognostic factor for disease-free survival (DFS, P=0.033) and overall survival (OS, P=0.020). Furthermore, the prognostic value of SII was also verified regardless of the histological type and pathological stage. The subgroup analysis demonstrated that patients with a high SII may benefit from adjuvant therapy (P=0.024 for DFS and P=0.012 for OS). Conclusion: An increased preoperative SII may independently predict the poor DFS and OS in patients with resectable NSCLC. SII may help select NSCLC patients who might benefit from adjuvant chemotherapy.

show abstract

“…Many studies had shown that NLR, AFP and brinogen were related to liver cancer patients OS 20,21 . In our study, we used the median of NLR and PLR as their cutoff values,the values were similar to that previously reported 22,23 . To our surprise, hematological indicators such as NLR, PLR and AFP were not prognosis factors of patients DFS.…”

Section: Discussionmentioning

confidence: 84%

Prognostic factors of disease-free survival in postoperative patients with hepatocellular carcinoma

Luo

zhang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) is a primary malignancy of the hepatocyte with high risk of invasion, metastasis and poor prognosis, which leads to a high mortality rate in recent years. This study aims to investigate the independent prognosis factors of DFS(disease free survival) in hepatocellular carcinoma patients after radical hepatectomy.Methods This study retrospectively analyzed 358 patients admitted to the 1st Affiliated Hospital of Anhui Medical College from December 2009 to December 2014. Categorical variables were analyzed by chi-square test. The survival curve was plotted by kaplan-meier method and tested by log-rank method. Univariate and multivariate Cox regression analyses were performed to determine the prognostic factors.Results Among the 344 patients with liver cancer, 298 cases (86.63%) are young patients (< 70 years), and 46 cases (13.37%) were elderly patients (≥ 70 years). There were no significant difference in gender, smoking history, alcohol consumption history, Body Mass Index (BMI), number of cancer nodules, tumor diameter, differentiation degree and TNM stage between the young and elderly groups (P > 0.05). However, history of hepatitis B and liver cirrhosis were more common in young patients than elderly (P=0.017, P༝0.000). The Kaplan-Meier curves indicated that elderly patients (higher than 70 years), TNM I-II stage and no history of hepatitis B had longer DFS. The univariate and multivariate analyses showed that age, TNM stage, History of hepatitis B were the independent factors for DFS.Conclusions Our findings suggested that age, TNM stage, history of hepatitis B were independent factors for predicting DFS of primary hepatocellular carcinoma patients. Patients older than 70 years had a better prognosis than young patients. Patients with early TNM stage and no history of hepatitis B had longer DFS.

show abstract

Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria

Cited by 79 publications

References 26 publications

<p>Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma</p>

<p>Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma</p>

Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer

Prognostic factors of disease-free survival in postoperative patients with hepatocellular carcinoma

Contact Info

Product

Resources

About